ArticleJACC. Advances2025
Plasma Ceramide C24:0/C16:0 Relates to Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hypertensive stretch regulates endothelial cell inflammation and apoptosis through ceramide metabolism.American journal of physiology. Cell physiology · 2026Article
- Ceramides: A Biologically Attractive Lipid and Advances in Acquisition Strategies.Antioxidants (Basel, Switzerland) · 2026Review
- Ceramides as Biomarkers and Pharmacological Targets in Heart Failure Pathophysiology.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCeramides are complex sphingolipids with pleiotropic effects. The ratio of specific ceramides (plasma C24:0/C16:0) is inversely related to incident heart failure (HF) and all-cause death in large, community-based cohorts without pre-existing HF. Whether plasma C24:0/C16:0 relates to outcomes in patients with HF with preserved ejection fraction (HFpEF) is unclear. We hypothesized plasma C24:0/C16:0 would be inversely related to, and independently predict, outcomes in HFpEF patients.
objectivesTo test our hypothesis, we used plasma samples, baseline, and outcomes data from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial. Findings were extended to a community-based cohort of HFpEF patients from the SHIP (Study of Health in Pomerania).
methodsPlasma C24:0/C16:0 was measured using well-validated liquid chromatography/tandem mass spectrometry. For TOPCAT, our primary endpoint was the composite of time to cardiovascular disease (CVD) death, hospitalization for HF, or aborted cardiac death episode. Secondary endpoints were time to CVD death and to HF hospitalization. For SHIP, CVD death was the primary endpoint and total mortality a secondary endpoint.
resultsIn 419 TOPCAT subjects (mean follow-up 3.3 years), lower plasma C24:0/C16:0 was associated with a higher risk of the primary endpoint; and HF hospitalization. In SHIP (N = 292; median follow-up 15.7 years), lower plasma C24:0/C16:0 was associated with a higher risk of CVD death and all-cause mortality in the SHIP cohort.
conclusionsLow plasma C24:0/C16:0 is independently associated with CVD death, all-cause mortality, and HF hospitalization in patients with HFpEF and may provide insight into novel treatment targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.